Literature DB >> 23643459

Differences in rate of functional decline across three dementia types.

Dawn P Gill1, Rebecca A Hubbard, Thomas D Koepsell, Michael J Borrie, Robert J Petrella, David S Knopman, Walter A Kukull.   

Abstract

BACKGROUND: The purpose of this study was to estimate differences in rates of functional decline in Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and vascular dementia (VaD) and whether differences vary by age or sex.
METHODS: Data came from 32 U.S. Alzheimer's Disease Centers. The cohort of participants (n = 5848) were ≥60 years of age and had clinical dementia with a primary etiologic diagnosis of probable AD, DLB, or probable VaD; a Clinical Dementia Rating-Sum of Boxes score <16; and a duration of symptoms ≤10 years. Dementia diagnoses were assigned using standard criteria. Annual mean rate of change of the Functional Activities Questionnaire (FAQ) score was modeled using multiple linear regression with generalized estimating equations adjusted for demographics, comorbidities, years since onset, and cognitive status (mean follow-up = 2.0 years).
RESULTS: FAQ declined more slowly over time in those with VaD compared with AD (difference in mean annual rate of change: -0.91; 95% confidence interval [CI]: -1.68, -0.14). VaD participants also declined at a slower rate than DLB participants, but this difference was not statistically significant (-0.61; 95% CI: -1.45, 0.24). There was no significant difference between DLB and AD. Within each group, rate of decline was more rapid for the youngest participants.
CONCLUSIONS: In this sample, findings suggested that VaD patients declined in their functional abilities at a slower rate compared with AD patients and that there were no significant differences in rate of functional decline between patients with DLB compared with those with either AD or VaD. These results may provide guidance to clinicians about average expected rates of functional decline in three common dementia types.
Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Dementia with Lewy bodies; Disease progression; Functional decline; Instrumental activities of daily living; Vascular dementia

Mesh:

Year:  2013        PMID: 23643459      PMCID: PMC3766452          DOI: 10.1016/j.jalz.2012.10.010

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  29 in total

1.  Cognitive and functional decline in African Americans with VaD, AD, and stroke without dementia.

Authors:  David L Nyenhuis; Philip B Gorelick; Sally Freels; David C Garron
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

2.  Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients.

Authors:  Anders Gustavsson; Per Brinck; Niklas Bergvall; Katarzyna Kolasa; Anders Wimo; Bengt Winblad; Linus Jönsson
Journal:  Alzheimers Dement       Date:  2011-05       Impact factor: 21.566

3.  Predictors of progression in patients with AD and Lewy bodies.

Authors:  O L Lopez; S Wisniewski; R L Hamilton; J T Becker; D I Kaufer; S T DeKosky
Journal:  Neurology       Date:  2000-05-09       Impact factor: 9.910

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Measurement of functional activities in older adults in the community.

Authors:  R I Pfeffer; T T Kurosaki; C H Harrah; J M Chance; S Filos
Journal:  J Gerontol       Date:  1982-05

6.  Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.

Authors:  Timo Erkinjuntti; Alexander Kurz; Serge Gauthier; Roger Bullock; Sean Lilienfeld; ChandrasekharRao Venkata Damaraju
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

Review 7.  Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention.

Authors:  Gustavo C Román
Journal:  Med Clin North Am       Date:  2002-05       Impact factor: 5.456

8.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

Review 9.  Dementia with Lewy bodies.

Authors:  Ian McKeith; Jacobo Mintzer; Dag Aarsland; David Burn; Helen Chiu; Jiska Cohen-Mansfield; Dennis Dickson; Bruno Dubois; John E Duda; Howard Feldman; Serge Gauthier; Glenda Halliday; Brian Lawlor; Carol Lippa; Oscar L Lopez; João Carlos Machado; John O'Brien; Jeremy Playfer; Wayne Reid
Journal:  Lancet Neurol       Date:  2004-01       Impact factor: 44.182

10.  Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia.

Authors:  Christian K Andersen; Kim U Wittrup-Jensen; Anette Lolk; Kjeld Andersen; Per Kragh-Sørensen
Journal:  Health Qual Life Outcomes       Date:  2004-09-21       Impact factor: 3.186

View more
  10 in total

1.  Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

Authors:  Marie-Hélène Pilon; Stéphane Poulin; Marie-Pierre Fortin; Michèle Houde; Louis Verret; Rémi W Bouchard; Robert Laforce
Journal:  Neurology (ECronicon)       Date:  2016-03-11

2.  Frequency and impact of informant replacement in Alzheimer disease research.

Authors:  Joshua D Grill; Yan Zhou; Jason Karlawish; David Elashoff
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jul-Sep       Impact factor: 2.703

3.  Impact of the Presence of Select Cardiovascular Risk Factors on Cognitive Changes among Dementia Subtypes.

Authors:  Katherine E Irimata; Brittany N Dugger; Jeffrey R Wilson
Journal:  Curr Alzheimer Res       Date:  2018       Impact factor: 3.498

Review 4.  Genetic markers in biological fluids for aging-related major neurocognitive disorder.

Authors:  S A Castro-Chavira; T Fernandez; H Nicolini; S Diaz-Cintra; R A Prado-Alcala
Journal:  Curr Alzheimer Res       Date:  2015       Impact factor: 3.498

5.  Comorbidity profile in dementia with Lewy bodies versus Alzheimer's disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry.

Authors:  Seyed-Mohammad Fereshtehnejad; Soheil Damangir; Pavla Cermakova; Dag Aarsland; Maria Eriksdotter; Dorota Religa
Journal:  Alzheimers Res Ther       Date:  2014-10-06       Impact factor: 6.982

6.  A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial for Efficacy of Acetyl-L-carnitine in Patients with Dementia Associated with Cerebrovascular Disease.

Authors:  YoungSoon Yang; Hojin Choi; Chan-Nyoung Lee; Yong Bum Kim; Yong Tae Kwak
Journal:  Dement Neurocogn Disord       Date:  2018-03-31

7.  Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia.

Authors:  Marco Zuin; Antonio Cherubini; Stefano Volpato; Luigi Ferrucci; Giovanni Zuliani
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

Review 8.  An algorithmic approach to structural imaging in dementia.

Authors:  Lorna Harper; Frederik Barkhof; Philip Scheltens; Jonathan M Schott; Nick C Fox
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-10-16       Impact factor: 10.154

Review 9.  Application of Optical Coherence Tomography in the Detection and Classification of Cognitive Decline.

Authors:  Moon J Lee; Alison G Abraham; Bonnielin K Swenor; A Richey Sharrett; Pradeep Y Ramulu
Journal:  J Curr Glaucoma Pract       Date:  2018-03-01

10.  Preexisting Dementia Is Associated with Increased Risks of Mortality and Morbidity Following Major Surgery: A Nationwide Propensity Score Matching Study.

Authors:  Yu-Ming Wu; Hsien-Cheng Kuo; Chun-Cheng Li; Hsiang-Ling Wu; Jui-Tai Chen; Yih-Giun Cherng; Tzeng-Ji Chen; Ying-Xiu Dai; Hsin-Yi Liu; Ying-Hsuan Tai
Journal:  Int J Environ Res Public Health       Date:  2020-11-14       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.